New drug targets Hard-to-Treat cancers in early trial
NCT ID NCT06818812
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 24 times
Summary
This early-stage study tests an experimental drug called INCB186748 in 30 adults with advanced or spreading solid tumors that have a specific genetic mutation (KRAS G12D). The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. Participants must have tried other treatments first or have no standard options left.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Florida Cancer Specialists
Sarasota, Florida, 34232, United States
-
Georgetown University Hospital
Washington D.C., District of Columbia, 20007, United States
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Jefferson University Hospitals
Philadelphia, Pennsylvania, 19107, United States
-
Md Anderson Cancer Center
Houston, Texas, 77030, United States
-
Sarah Cannon Research Institue At Healthone
Denver, Colorado, 80218, United States
-
Scri Oncology Partners
Nashville, Tennessee, 37203, United States
-
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins
Baltimore, Maryland, 21287-7049, United States
-
UCLA Healthcare Hematology-Oncology
Santa Monica, California, 90404, United States
Conditions
Explore the condition pages connected to this study.